The BNLI: Past and present

Clinical Oncology

Volumn 10, Issue 4, 1998, Pages 212-218

  Vaughan Hudson, B ^b   Linch, D C ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL RESEARCH; DATA BASE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOXICITY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG TOXICITY; LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; TISSUE REACTION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

EID: 0031687092     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80003-4     Document Type: Review

References (56)

1. Jelliffe AM. Hodgkin's disease: the pendulum swings. Clin Radiol 1979;30:121-37.
2. Jelliffe AM, Thomson AD. The prognosis in Hodgkin's disease. Br J Cancer 1955;9:21-36.
3. Jelliffe AM, Vaughan Hudson G. The evolution of the British National Lymphoma Investigation (BNLI report no. 5). Clin Radiol 1981;32:483-90.
4. Bennett MH, Tu A, Vaughan Hudson B. Analysis of grade 1 Hodgkin's disease (BNLI report no. 6). Clin Radiol 1981;32:491-8.
5. Bennett MH, MacLennan KA, Easterling MJ, et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no 22). Clin Raidol 1983;34:497-501.
6. MacLennan KA, Bennett MH, Tu A. Relationship of histopathologic features to survival in noodular sclerosing Hodgkin's disease. Cancer 1989;64:1686-93.
7. MacLennan KA, Vaughan Hudson B, Jelliffe AM, et al. The pretreatment peripheral blood lymphocyte count in 1100 patients with Hodgkin's disease: the prognostic significance and the relationship to the presence of systemic symptoms. Clin Oncol 1981;7:333-9.
8. Vaughan Hudson B, MacLennan KA, Easterling MJ, et al. The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23). Clin Radiol 1983;34:503-6.
9. MacLennan KA, Vaughan Hudson B, Easterling MJ, et al. The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21). Clin Radiol 1983;34:491-5.
10. Vaughan Hudson B, MacLennan KA, Bennett MH, et al. systemic disturbance in Hodgkin's disease and its relations to histopathology and prognosis (BNLI report no. 30). Clin Radiol 1987,38:257-61.
11. Vaughan Hudson B, Linch DC, MacIntrye EA, et al. Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI report no. 31). J Clin Pathol 1987;40:247-50.
12. Schey S, Vaughan Hudson B, Linch DC, et al. The prognostic influence of mediastinal bulk in pathological Stage IIA Hodgkin's disease treated initially with radiotherapy. Clin Oncol 1989;1:28-32.
13. MacIntyre EA, Vaughan Hudson B, Linch DC. The value of staging bone marrow trephine biopsy in Hodgkin's disease (BNLI report no. 28). Eur J Haematol 1987;39:66-70.
14. Haybittle JL, Hayhoe FGJ, Easterling MJ, et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985;i:967-72.
15. Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved field radiotherapy in clinical Stage 1A and 2A Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 1994;12:288-96.
16. Williams MV, Moody M, Pratt J, et al. BNLI pilot studies of neoadjuvant therapy in clinical Stage 1A and 2A Hodgkin's disease [abstract]. 6th International Conference on malignant lymphoma, Lugano. 1996;404:110.
17. De Vita VT, Serpick AA, Carbone PP, et al. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
18. BNLI Report: Value of prednisone in combination chemotherapy of Stage 4 Hodgkin's disease. BMJ 1975;ii:413-4.
19. Hancock BW. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Radiother Oncol 1986;7:215-21.
20. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation randomise study of MOPP (mustine, Oncovin, procarbazine, prednisoline) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease - long term results. Br J Cancer 1991;63:579-82.
21. Linch DC, Vaughan Hudson B. The management of Hodgkin's disease and the non-Hodgkin's lymphomas. In: Hoffbrand AV, editor. Recent advances in clinical haematology (number five). London: Churchill Livingstone, 1988;211-42.
22. Hancock BW, Vaughan Hudson G, Vaughan Hudsn B, et al. LOPP alternating with EVAP is superior to LOPP alone in the treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol 1992;10:1252-8.
23. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, et al. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP. A prematurely terminated British National Lymphoma Investigation randomised trial. Ann Oncol 1994;5(suppl 2):S5117-20.
24. Hancock BW, Cullen MH, Vaughan Hudson G, et al. Alternating ChIVPP/PABIOE is better than PABIOE alone as initial chemotherapy for advanced Hodgkin's disease: first results of a British National Lymphoma Investigation (BNLI)/ Central Lymphoma Group (CLG) study [abstract]. Eur J Cancer 1997;33(suppl 8):1186.
25. Gribben JG, Vaughan Hudson B, Linch DC. The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas. Hematol Oncol 1987;5:281-93.
26. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4.
27. Khwaja A, Linch DC, Goldstone AH, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol 1992;82:317-23.
28. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomised BNLI trial. Br J Haematol 1997;99:933-8.
29. MacLennan KA, Bennett MH, Bosq J, et al. The histology and immunochemistry of Hodgkin's disease: its relationship to prognosis and clinical behaviour. pp 17-25. In: Somers R, Henry-Omar M, Meerwaldt JH, Carde P, editors. Treatment Strategy in Hodgkin's Disease. Colloque Inserm Vol. 196. London and Paris: John Libbey, 1990.
30. Meerwaldt JH, Van Glabbeke M, Vaughan Hudson B. Prognositc Factors for Stage 1 and 2 Hodgkin's disease. pp 37-50. In: Somers R, Henry-Omar M, Meerwaldt JH, Carde P, editors. Treatment Strategy in Hodgkin's Disease. Colloque Inserm Vol. 196. London and Paris: John Libbey, 1990.
31. Vaughan Hudson B. Hodgkin's disease treatment strategy - stage 1-2. pp 83-6. In: Somers R, Henry-Omar M, Meerwaldt JH, Carde P, editors. Treatment Strategy in Hodgkin's Disease. Colloque Inserm Vol. 196. London and Paris: John Libbey, 1990.
32. Bennett MH, MacLennan KA, Vaughan G, et al. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. Ann Oncol 1991;2(suppl 2):83-92.
33. Devereux S, Selassie TG, Vaughan Hudson G, et al. Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation. BMJ 1990;301:1077-80.
34. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
35. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationship to host factors, histology, and stage of Hodgkin's disease, and splenectomy. Br J Cancer 1993;68:1006-11.
36. Swerdlow AJ, Douglas AJ, Vaughan Hudson O, et al. Completeness of cancer registration in England and Wales: an assessment based on 2145 patients with Hodgkin's disease independently registered by the British National Lymphoma Investigation. Br J Cancer 1993;67:326-9.
37. Swerdlow AJ, Jacobs PA, Marks A, et al. Fertility, reproductive outcomes, and health of offspring, of patients treated for Hodgkin's disease. Br J Cancer 1996;74:291-6.
38. Vaughan Hudson B, Vaughan Hudson G, Linch DC, et al. Late mortality in young BNLI patients cured of Hodgkin's disease. Ann Oncol 1994;5(suppl 2):S65-6.
39. Vaughan Hudson B, Linch DC, Anderson L, et al. Probability of relapse and survival of BNLI patients in sustained complete remission [abstract]. Ann Oncol 1996;7(suppl 3):174.
40. Spry NA, Lamb DS, Vaughan G, et al. Localised Grade I non-Hodgkin's lymphoma: results of treatment with radiotherapy alone in 88 patients. Clin Oncol 1989;1:33-8.
41. Lamb DS, Vaughan Hudson O, Easterling MJ, et al. Localised grade 2 non-Hodgkin's lymphoma: results of treatment with radiotherapy (BNLI report no. 24). Clin Radiol 1984;35:253-60.
42. Kelsey SM, Newland AC, Vaughan Hudson G, et al. A British National Lymphoma Investigation trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade localised non-Hodgkin's lymphoma. Med Oncol 1994;11(1):19-25.
43. Phillips DL. Radiotherapy in the treatment of localised non-Hodgkin's lymphoma (BNLI report no. 16). Clin Radiol 1981; 32:543-6.
44. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin's lymphoma: long term follow up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088-93.
45. Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G, et al. The clinical ontcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation group. Br J Haematol 1997;99:842-7.
46. British National Lymphoma Investigation report. A prospective comparison of combination chemotherapy with total body irradiation in the treatment of advanced non-Hodgkin's lymphoma. Clin Oncol 1981;7:193-200.
47. De Lord C, Newland AC, Vaughan Hudson B, et al. Failure of IMVP-16 as second line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol 1992;10:81-6.
48. Linch DC, Vaughan Hudson B, Hancock BW, et al. A randomised comparison of a third generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Br J Cancer 1996;74:318-22.
49. Cunningham D, Mainwaring PN, Gregory W, et al. A BNLI randomised study of PadriaCEBO vs PmitCEBO in patients with high grade lymphoma over 60 years of age [abstract]. Proc ASCO 1998; in press.
50. Linch DC, Vaughan Hudson B, Anderson L, et al. Impact of high dose salvage therapy (BEAM) on overall survival in younger patients with advanced large cell lymphomas entered in BNLI trials. Ann Oncol 1997;8(suppl 1):S63-5.
51. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood 1996;88:1046-51.
52. Isaacson PG, Wright DH. Malignant lymphoma of mucosa associated tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410.
53. Crellin AM, Vaughan Hudson B, Bennett MH. Non-Hodgkin's lymphoma of the testis. Radiother Oncol 1993;27:99-106.
54. Morton JE, Leyland MJ, Vaughan Hudson G, et al. Primary gastrointestinal non-Hodgkin's lymphoma: a review of 175 British National Lymphoma Investigation cases. Br J Cancer 1993;67:776-82.
55. Laing RW, Hoskin P Vaughan Hudson B, et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol 1994;6:300-4.
56. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-7.